DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Endothelial Dysfunction and Diabetes

Information source: Assistance Publique - H˘pitaux de Paris
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 1 Diabetes Mellitus

Intervention: Trinitrin (Drug); Neosynephrine 10% collyrium (Drug); Iontophoresis with acetylcholine delivery (Drug); Dynamic Vessel Analyzer (Device)

Phase: N/A

Status: Completed

Sponsored by: Assistance Publique - H˘pitaux de Paris

Official(s) and/or principal investigator(s):
Am├ęlie LECLEIRE-COLLET, MD, Principal Investigator, Affiliation: Assistance Publique - H├┤pitaux de Paris
Pascale MASSIN, MD, PhD, Principal Investigator, Affiliation: Assistance Publique - H├┤pitaux de Paris

Summary

The aim of the study is to progress in the understanding of the early retinal vascular and neural abnormalities in patients with diabetes, using a new device, the Dynamic Vessel Analyzer. The Dynamic Vessel Analyzer allows to measure the diameter of the retinal vessels and to assess how it varies in presence of various stimuli. Then, we will be able to assess if a vascular and/or a neural dysfunction is present early in patient with diabetes.

Clinical Details

Official title: Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit)

Secondary outcome:

Presence of a peripheral endothelial dysfunction

Correlation between retinal and peripheral endothelial dysfunction (assessment study visit)

Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin.

Detailed description: Twenty patients with type 1 diabetes without diabetic retinopathy and without arterial hypertension will be compared with 20 sex and aged-matched healthy control subjects. To assess the presence of retinal endothelial dysfunction, the variations of the diameters of the retinal vessels will be assessed using the Dynamic Vessel Analyzer, before and after flicker light stimulation, sublingual nitroglycerin, neosynephrine eyedrops, and isometric contraction. To assess the presence of peripheral endothelial dysfunction, the microcirculation of the forearm skin will be studied using iontophoresis with acetylcholine delivery, and heat delivery, both coupled with blood flow measurement using laser Doppler. An intravital capillaroscopy of the phalanx skin will be performed. The serum levels of CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin will also be measured.

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- For diabetic patients :

- age between 20 and 60

- type 1 diabetes mellitus

- diabetes duration of more than 5 years

- no diabetic retinopathy on fundus examination or fundus photographs

- no systemic hypertension (defined as systolic blood pressure > 140 mmHg,

diastolic blood pressure > 90 mmHg)

- For control subjects :

- sex and age matching with the diabetic patients

- no diabetes, no familial or personal history of elevated blood sugar

- Non-diabetic subjects, criteria defined by a fasting glucose <1. 10 g / l and an

HbA1c <6. 5% (according to Lariboisi├Ęre biochemistry laboratory HbA1c)

- no systemic hypertension (defined as systolic blood pressure > 140 mmHg,

diastolic blood pressure > 90 mmHg)

- Subject with a normal ophthalmologic examination

- For both diabetic patients and control subjects :

- Subject that has signed informed consent

- Subject affiliated to a social security

- Subject available for a period of 4 months

Exclusion Criteria:

- For both diabetic patients and control subjects :

- presence of cataract or history of cataract surgery

- intraocular pressure of more than 21 mmHg

- treatment with vasoactive drugs

- tobacco consumption of more than 20 cigarettes a day

- Contraindications to trinitrin administration: hypersensitivity to trinitrin,

treatment by sildenafil, heart disease, severe arterial hypotension, bradycardia, intracranial hypertension

- Clinical Raynaud syndrome

- Pregnant or breast-feeding subject

- Subject whose age is <18 and> 60 years on the day of inclusion

- Subject with cardiac disease, severe hypotension (BP <80/50 mmHg), a resting

heart rate below 50 beats / minute

- Subject intracranial hypertension

- Subject with a current consumption of drugs or drugs that may impact vasomotion

(antiglaucoma eye drops, vasodilators, antihypertensive drugs). Vasoactive drug use will be prohibited within 24 hours preceding the study.

- Subject has not signed an informed consent

- Subject not affiliated to a social security

- Subject not available for a period of 4 months

Locations and Contacts

H├┤pital LARIBOISIERE Service d'Ophtalmologie, Paris 75010, France
Additional Information

Starting date: January 2011
Last updated: July 2, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017